Singapore markets open in 5 hours 44 minutes

Straits Times Index
3,239.03
+26.39(+0.82%)
S&P 500
3,988.50
+17.51(+0.44%)
Dow
32,500.48
+262.95(+0.82%)
Nasdaq
11,808.54
-15.42(-0.13%)
Bitcoin USD
27,066.03
-774.62(-2.78%)
CMC Crypto 200
589.27
-18.19(-2.99%)

AZN Jul 2023 62.500 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

8.70

+1.40

(+19.18%)

As of 01:22PM EDT. Market open.

Zacks
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Business Wire
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1
Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.